Common stock, par value $0.001 per share
- Symbol
- KRRO
- Exchange
- NASDAQ
- Classification
- COMMON
Current Report · Items 8.01, 9.01 · 8-K
Korro Bio, Inc.
Other Events
Item 8.01. Other Events. On May 19, 2026, Korro Bio, Inc. issued a press release announcing the addition of KRRO-111 for the potential treatment of Alpha-1 Antitrypsin Deficiency to its pipeline of therapeutic programs in development. A copy of the press release is filed as Exhibit 99.1 to this current report on Form 8-K and is incorporated herein by reference. Korro Bio, Inc.…
Company context
Korro is a clinical-stage biopharmaceutical company leveraging a novel oligonucleotide promoted editing of RNA (OPERA®) platform to develop a new class of genetic medicines for rare and highly prevalent diseases. OPERA provides precise, tissue-directed delivery of RNA-editing oligonucleotides (REOs) that modify the targeted native mRNA transcript to repair or form a de novo protein with enhanced functionality. The platform combines a suite of capabilities consisting of sophisticated knowledge of transcription biology through ADAR proteins (Adenosine Deaminases Acting on RNA), machine learning optimization of REOs, linker chemistry expertise, along with use of a highly targeted tissue-specific delivery methodology. As such, the OPERA platform has enabled Korro to generate and advance a portfolio of differentiated programs that are designed to harness the body’s natural RNA editing process, providing precise yet transient single base edits to produce therapeutic proteins with augmented activity versus its endogenous counterpart. By editing RNA instead of DNA, Korro is expanding the reach of genetic medicines by delivering additional precision and tunability, which has the potential for increased specificity and improved long-term tolerability. Using an REO-based approach, Korro expects to bring its medicines to patients by leveraging its proprietary OPERA platform with precedented delivery modalities, including N-acetylgalactosamine (GalNAc) conjugated for delivery for subcutan
Current securities
Historical securities (1)
Registered securities in this filing
Korro Bio, Inc. · 8-K · Filed 2026-05-19
Disclosure sections
Item 8.01Item 8.01 - Other Events
Item 8.01. Other Events.
On May 19, 2026, Korro Bio, Inc. issued a press release announcing the addition of KRRO-111 for the potential treatment of Alpha-1 Antitrypsin Deficiency to its pipeline of therapeutic programs in development. A copy of the press release is filed as Exhibit 99.1 to this current report on Form 8-K and is incorporated herein by reference.
Korro Bio, Inc. also updated its corporate presentation for use in meetings with investors, analysts and others. A copy of certain updated slides is filed as Exhibit 99.2 to this current report on Form 8-K and is incorporated herein by reference.
Filed exhibits (2)
EX-99.1 2 krro-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Korro Selects KRRO-111 as Development Candidate for the Potential Treatment of Alpha-1 Antitrypsin Deficiency (AATD) • Potential best-in-class therapeutic delivered subcutaneously (GalNAc-conjugated oligonucleotide) for a debilitating genetic condition impacting both the liver and lungs • Demonstrated >90% editing of SERPINA1 transcript in vivo translating into ~90% repaired functional alpha-1 antitrypsin (AAT) protein in plasma in a mouse model of AATD • Demonstrated a near elimination of active Z-protein production while showing progressive clearance of pre-existing aggregates in a mouse model of AATD • Pre-clinical data highlighted the possibility of repeat dose therapy to achieve the functional equivalent of a DNA modification without altering the genome CAMBRIDGE, Mass., May 19, 2026 - Korro Bio, Inc. (Korro) (Nasdaq: KRRO), a biopharmaceutical company leveraging a novel Oligonucleotide Promoted Editing of RNA (OPERA®) platform to develop a new class of genetic medicines for rare and highly prevalent diseases, today announced the addition of KRRO-111 for the potential treatment of AATD to its pipeline of therape…
Open exhibit ↗EX-99.2 3 krro-ex99_2.htm EX-99.2 May 2026 Corporate Presentation Exhibit 99.2 Forward-Looking Statement and Disclaimers CONFIDENTIAL Forward-Looking Statements Certain statements in this presentation may constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements include, but are not limited to, express or implied statements regarding expectations, hopes, beliefs, intentions or strategies of Korro Bio, Inc. (Korro) regarding the future including, without limitation, express or implied statements regarding: Korro’s ability to activate a biological pathways with RNA editing; Korro’s ability to create value in 2026 and beyond; Korro’s cash runway and uses thereof; the timing of updates on Korro's assets; the timing of and ability to submit a regulatory filing for KRRO-121; the market opportunity for KRRO-121; KRRO-121’s pan-urea cycle disorder (UCD) potential; KRRO-121’s first-in-class potential as a treatment for ammonia control; KRRO-121’s blockbuster potential in multiple indications; KRRO-111's best-in-class potential as a treatment for Alpha-1 Antitrypsin Deficiency (AATD); and ti…
Open exhibit ↗